Grow-NY win accelerates Barnwell Bio’s expansion plans

A hen in an open field
Organic poultry production comes with specific disease threats, requiring producers to develop a proactive strategy (Getty Images/iStockphoto)

Barnwell Bio holds off on raising its Series A round until end of 2027 as the animal health monitoring company focuses on scaling and testing its technology

Nearly 10 months after raising its seed round, Barnwell Bio has won the grand prize at the eighth annual 2026 Grow-NY Food and Agriculture Business Competition, providing the start-up with $1 million in capital to assist with the company’s scale-up journey, including expanding its team and bringing its biosurveillance technology to more farms and animals.

Launched in 2024, Barnwell uses shotgun metagenomic sequencing on environmental samples to detect if certain bacteria and diseases like avian flu, egg drop syndrome, and other diseases, are present, allowing producers and animal health experts to better respond to outbreak, AgNavigator reported previously.

Barnwell will use the prize money to grow its presence in New York, with a keen focus on expanding the tech to the growing number of organic and pasture-raised poultry producers in the state, Michael Rhys, CEO and co-founder of Barnwell Bio, told AgNavigator. Sustainable farming practices improve conditions for animals, but they often come with unique disease challenges, Rhys noted.

“Consumers and regulators are increasing their demands around animal welfare standards, and so they’re requiring things like cage-free operations, outdoor access, which are obviously really helpful in some ways, but they also introduce a lot of new disease pressure. And we see a lot of challenges with some of these new management styles, whether it’s organic or pasture raised,” Rhys elaborated.

Where Barnwell goes after winning the Grow-NY prize

Barnwell will also use the award winnings to expand its technology into other animals with swine production pilot underway and plans to move into dairy, Rhys noted.

Additionally, the company partnered with animal health companies and recently partnered with biotech start-up Neion Bio to provide its biosurveillance to track the health of Neion’s flock.

Neion Bio is a fellow New York start-up that uses genetic engineering in chickens to produce recombinant proteins, like enzymes, fusion proteins, and monoclonal antibodies, inside the egg whites, Barnwell shared.

Looking ahead, Barnwell is taking on some capital to grow its business, but the company is waiting to launch its Series A until the end of 2027, given some of the market dynamics, Rhys noted.

“We’re trying to be really thoughtful and deliberate around our fundraising, and so we’ll see how the market changes in the next few months,” Rhys elaborated.